Analysis of defect mode switching response in one-dimensional photonic crystal with a nematic liquid crystal defect layer

We analyze the dynamic response and optical properties of a high-speed defect mode switching that is based on a tunable defect mode in a one-dimensional photonic crystal with a nematic liquid crystal defect layer. The electro-optic responses of the defect mode switching are calculated considering the director distributions in the defect layer, which are determined using continuum theory. The calculated defect mode switching exhibits a response on the order of microseconds in spite of the use of the reorientation of nematic liquid crystal molecules. From the calculation, it is found that the fast response is realized using a narrow peak shift and a fast part of the molecular reorientation. Furthermore, the dependences of the switching response are clarified on several physical parameters.This article may be downloaded for personal use only. Any other use requires prior permission of the author and AIP Publishing. This article appeared in Ryotaro Ozakia, Hiroshi Moritake, Katsumi Yoshino, and Masanori Ozaki, J. Appl. Phys. 101, 033503 (2007) and may be found at https://doi.org/10.1063/1.2432877

Electro-optic switching in spin-coated ferroelectric mesomorphic polymer films and its analysis

This article may be downloaded for personal use only. Any other use requires prior permission of the author and AIP Publishing. This article appeared in Sadahito Uto, Hiroshi Moritake, Masanori Ozaki, Kent Skarp, and Bertil Helgee, Journal of Applied Physics 79, 4444 (1996) and may be found at https://doi.org/10.1063/1.361754

Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector

Background: Disease modeling with patient-derived induced pluripotent stem cells (iPSCs) is a powerful tool forelucidating the mechanisms underlying disease pathogenesis and developing safe and effective treatments. Patientperipheral blood (PB) cells are used for iPSC generation in many cases since they can be collected with minimuminvasiveness. To derive iPSCs that lack immunoreceptor gene rearrangements, hematopoietic stem and progenitorcells (HSPCs) are often targeted as the reprogramming source. However, the current protocols generally requireHSPC mobilization and/or ex vivo expansion owing to their sparsity at the steady state and low reprogrammingefficiencies, making the overall procedure costly, laborious, and time-consuming.Methods: We have established a highly efficient method for generating iPSCs from non-mobilized PB-derivedCD34+ HSPCs. The source PB mononuclear cells were obtained from 1 healthy donor and 15 patients and werekept frozen until the scheduled iPSC generation. CD34+ HSPC enrichment was done using immunomagnetic beads,with no ex vivo expansion culture. To reprogram the CD34+-rich cells to pluripotency, the Sendai virus vectorSeVdp-302L was used to transfer four transcription factors: KLF4, OCT4, SOX2, and c-MYC. In this iPSC generationseries, the reprogramming efficiencies, success rates of iPSC line establishment, and progression time wererecorded. After generating the iPSC frozen stocks, the cell recovery and their residual transgenes, karyotypes, T cellreceptor gene rearrangement, pluripotency markers, and differentiation capability were examined.Results：We succeeded in establishing 223 iPSC lines with high reprogramming efficiencies from 15 patients with 8 different disease types. Our method allowed the rapid appearance of primary colonies (~ 8 days), all of which were expandable under feeder-free conditions, enabling robust establishment steps with less workload. After thawing, the established iPSC lines were verified to be pluripotency marker-positive and of non-T cell origin. A majority of the iPSC lines were confirmed to be transgene-free, with normal karyotypes. Their trilineage differentiation capability was also verified in a defined in vitro assay.Conclusion：This robust and highly efficient method enables the rapid and cost-effective establishment of transgene-free iPSC lines from a small volume of PB, thus facilitating the biobanking of patient-derived iPSCs and their use for the modeling of various diseases